— Launch of Regenerative Medicine Operations and Advancement of Joint Research Outcomes —

CERUSTAR PTE. LTD., a Singapore-based biotechnology company, has formally established its Japanese subsidiary, Cellastar Co., Ltd. (Head Office: Naka-ku, Yokohama, Kanagawa Prefecture; Representatives: Shigeo Murakami and Kazuhiko Horikoshi), on March 6, 2023, and has commenced operations in Japan in the field of regenerative medicine.

CERUSTAR PTE. LTD. has engaged in joint research with Singapore’s Agency for Science, Technology and Research (A*STAR), focusing on the development of advanced cell culture technologies. The collaborative research aims to enhance both the efficiency and quality of adipose-derived stem cell cultivation and to reduce oxidative stress in cultured cells intended for clinical applications.

As demand for regenerative medicine continues to increase, achieving higher quality and greater scalability in adipose-derived stem cell cultivation remains a challenge for the industry. The application of outcomes derived from this joint research to cell processing and clinical implementation processes is expected to contribute significantly to the advancement of life sciences in Japan.